

Title (en)
CEPHALOSPRIN DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

Publication
EP 0000500 A3 19790627

Application
EP 78100367 A 19780711

Priority
LU 77788 A 19770718

Abstract (en)
[origin: ES471812A1] Acylamido-3-cephem-4-carboxylic acid compounds of the formula < IMAGE > (I) < IMAGE > in which the index n represents an integer of from 1 to 4, the index m represents 0 or 1, X represents oxygen, sulphur or an -NH- group, W represents a -CO-, -CO-NHSO₂- or -SO₂NH-CO- group, or X-W together represent a -CO- or -CO-NHSO₂- group, A represents optionally substituted phenylene, thienylene or furylene, Y represents hydrogen, hydroxyl, formyloxy, amino or sulpho optionally present in salt form, and Z represents hydrogen, or Y and Z together represent an oxo group or an =N-O-R DEG group in which R DEG represents hydrogen or optionally substituted lower alkyl, R1 represents hydrogen, lower alkyl, lower alkoxy, halogen or a group of the formula -CH₂-R₂ in which R₂ is a free, esterified or etherified hydroxy or mercapto group or a quaternary ammonium group, and R₃ represents hydrogen or methoxy, wherein the carboxyl groups are optionally esterified in a form that can be split under physiological conditions, and the salts thereof, are obtained by liberating the functional group(s) in a starting compound of the formula I in which at least one of the functional groups present is protected. The compounds are effective in vitro and in vivo against gram-positive and gram-negative bacteria and cocci.

IPC 1-7
C07D 501/00; **A61K 31/545**; **C07D 307/54**; **C07D 333/24**; **C07C 103/46**

IPC 8 full level
C07D 499/06 (2006.01); **A61K 31/545** (2006.01); **A61K 31/546** (2006.01); **A61P 31/04** (2006.01); **C07D 307/34** (2006.01); **C07D 307/52** (2006.01); **C07D 307/54** (2006.01); **C07D 333/04** (2006.01); **C07D 333/24** (2006.01); **C07D 501/20** (2006.01); **C07D 501/32** (2006.01); **C07D 501/34** (2006.01); **C07D 501/57** (2006.01); **C07D 501/59** (2006.01); **C07D 501/00** (2006.01)

CPC (source: EP US)
A61P 31/04 (2017.12 - EP); **C07D 307/52** (2013.01 - EP US); **C07D 307/54** (2013.01 - EP US); **C07D 333/24** (2013.01 - EP US)

Citation (search report)
• FR 2228476 A1 19741206 - FUJISAWA PHARMACEUTICAL CO [JP]
• FR 2228475 A1 19741206 - SMITHKLINE CORP [US]
• FR 2235695 A1 19750131 - FUJISAWA PHARMACEUTICAL CO [JP]

Cited by
EP0059683A3; EP0016296A1; US4740329A; EP0031794A3; US4464366A

Designated contracting state (EPC)
BE CH DE FR GB LU NL SE

DOCDB simple family (publication)
EP 0016900 A1 19801015; **EP 0016900 B1 19831116**; AT 361621 B 19810325; AT A515678 A 19800815; AU 3806578 A 19800117; AU 522514 B2 19820610; CA 1113453 A 19811201; DE 2861767 D1 19820609; DE 3065568 D1 19831222; DK 319178 A 19790119; EP 0000500 A2 19790207; EP 0000500 A3 19790627; EP 0000500 B1 19820428; ES 471812 A1 19791016; IE 47032 B1 19831130; IE 781431 L 19790118; IL 55152 A0 19780929; IL 55152 A 19820730; IT 7850324 A0 19780717; JP S5452094 A 19790424; NZ 187852 A 19810316; US 4467101 A 19840821; ZA 784050 B 19790829

DOCDB simple family (application)
EP 80100097 A 19780711; AT 515678 A 19780717; AU 3806578 A 19780717; CA 307382 A 19780714; DE 2861767 T 19780711; DE 3065568 T 19780711; DK 319178 A 19780717; EP 78100367 A 19780711; ES 471812 A 19780717; IE 143178 A 19780717; IL 5515278 A 19780717; IT 5032478 A 19780717; JP 8684778 A 19780718; NZ 18785278 A 19780713; US 42053482 A 19820920; ZA 784050 A 19780717